Foghorn TherapeuticsFHTX
Recorded

Foghorn Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration21 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael SchmidtAnalyst

us today, we have Adrian Gottschalk, President and CEO. Adrian, welcome. Thanks for joining us.

Adrian GottschalkPresident and CEO

Thank you for having me.

Michael SchmidtAnalyst

So Adrian, after the FHD-909 decision, how would you describe Foghorn's strategy and priorities today?

Adrian GottschalkPresident and CEO

Sure. So obviously, unfortunately, we had to, along with our colleagues at Lilly, we made the decision not to proceed forward with our SMARCA2 program, the FHD-909 program. I think the first iteration, if you will, of what we've been working on was predominantly chromatin-related, the BAF complex obviously, which we were targeting a subunit of that with the 909 program, as well as in the context of synthetic lethality. I sort of think about that as the first chapter, if you will, of the company. And post, obviously, this clinical study, along with other data that we had generated over several years with other molecules that we had targeted some of this biology with, we sort of turned that page. So we're moving away, or have moved away from targeting the BAF complex.

Adrian GottschalkPresident and CEO

We've moved away from synthetic lethality, and the pipeline on which we're presently focused is looking at where there's just clear and frank dependency in oncology, but also where we're able to use our platform to selectively drug challenging targets, which has resulted in this novel I&I program that we've subsequently disclosed, where we're going into the area of inflammatory bowel disease, so ulcerative colitis and Crohn's. Then more broadly, using the platform, which I'll distill and oversimplify to say we're really good at working with complex and difficult-to-make proteins, coupled with very extensive chemistry, including degradation, but now induced proximity, where we're going to harness some novel biology within the endoplasmic reticulum to effectively go after and get rid of secreted proteins, cytokines, and transmembrane proteins. But it's not just limited to those types of proteins.

Adrian GottschalkPresident and CEO

So that's effectively the evolution, if you will, of the company, harnessing the platform capabilities that we built to go after chromatin remodeling complexes, but now evolving into areas beyond that and beyond synthetic lethality.

Michael SchmidtAnalyst

Got you. I don't want to spend too much time on 909, but just any insights gained from the study, as it pertains to SMARCA2 as a target, would you see that as being validated or perhaps not a useful target in itself?

Adrian GottschalkPresident and CEO

Yeah. So from our perspective, I believe, and obviously in concert with Lilly, we developed an excellent molecule in 909. Generally very selective. It was overall, as we dose escalated through that study, it was generally safe and well tolerated. We were able to escalate obviously multiple times. At the end of the day, the view that we have is that what was very exciting preclinical data that frankly the industry as a whole at one point was excited about, our folks in the oncology area, the biology just didn't translate. So from my vantage point, it wasn't a function of could we have gotten a better molecule. We, I think, ran a really great clinical study, or I should say Lilly, in collaboration with us, did. So from my perspective, there's something unfortunately flawed with our understanding of the biology, and hence the synthetic lethality.

Adrian GottschalkPresident and CEO

At least in the context of how we went after it, that is not an area of biology that we should sort of be exploring further.

Michael SchmidtAnalyst

Would you agree that it is pretty unlikely for other industry programs that address SMARCA2 to perhaps have a similar outcome at the end of the day?

Adrian GottschalkPresident and CEO

Yeah. I mean, I am not an absolutist. I think that is dangerous. But if I were allocating capital, given now that we have got evidence from obviously our colleagues at Prelude, they took a degrader approach with some limitations potentially there. We have taken an approach with an inhibitor. We had a degrader also in development with Lilly. In our hands, you had to get north of 95% plus degradation to even equal what we were able to do with the inhibitor. I personally would be skeptical, but I mean, that is why people run clinical trials. Hope springs eternal in the biotech industry, as you know. If I were sitting on a board and working on that target, I would be very skeptical about allocating further capital.

Michael SchmidtAnalyst

Okay, helpful. Where do you stand with the EP300 and CBP programs?

Adrian GottschalkPresident and CEO

Sure. These are paralog proteins, very, very similar. We've got two separate and distinct efforts ongoing after those targets. We're very excited by our EP300 program. This is looking at hematological malignancies, namely multiple myeloma and potentially diffuse large B-cell lymphoma, and potentially some others to come along. That program is on track to an IND by the end of 2027. We have a once-a-week subcutaneous formulated drug. We have some backup efforts also that might lend itself to oral delivery of a selective EP300 drug. We're particularly excited by the data that's being generated pre-clinically, but importantly also from our colleagues at CellCentric. They've done an excellent job of profiling their molecule, inobrodib, which has shown, in our opinion, very compelling efficacy in multiple myeloma. I know they're scheduled to have a presentation or a poster, I believe, at ASH, highlighting combination data with an anti-BCMA.

Adrian GottschalkPresident and CEO

They've already shown combination data with a fixed background of pomalidomide and dexamethasone. We see this as an orthogonal mechanism. I think the rate-limiting issue, at least from our perspective, is their drug hits both CBP and EP300, whereas if you're able to dial out the CBP portion and just hit EP300, you eliminate some of the thrombocytopenia and the platelet impacts that come with that. So, particularly excited by that program. Again, that's moving along with some lifecycle management activity there. Our CBP program, again, separate and distinct, that's targeting ER-positive breast cancer. Unfortunately, we took a bit of a delay with that program, as we announced back in August.

Adrian GottschalkPresident and CEO

The CRO with whom we were working in the May timeframe unfortunately lost their entire animal facility, so we've had to go back to the drawing board, as it were, with a bunch of other in vivo models with some other CROs. We're basically redoing a bunch of that work. We need to get to human dose projections, and we need to do some combination work with CDK4/6 and SERDs before we'll push that forward. But that's basically sitting there almost ready to go. It's a once-a-week, long-acting injectable formulation that's already gone through the dose range finding studies at this point.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day